Monte Rosa Therapeutics, Inc. (GLUE)
Nasdaq · Healthcare · Biotechnology
$10.27−2.19%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $876M
- 52-week range
- $7.24 – $25.77
- 52-week change
- +42.28%
- EPS (trailing)
- −$1.75
- Analyst rating
- 1.2 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $124M (+63.54%)
- Net income
- −$38.6M
- Operating margin
- −43.8%
- Free cash flow
- −$27.5M
From the company’s annual report on SEC EDGAR.
About Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis.
Headquarters: Boston, United States · 173 employees · monterosatx.com